ANXA1-high tumors were enriched in immunology-related pathways such as chemokine receptor–ligand interactions and interferon gamma and interleukin signaling, whereas ANXA1-low tumors were enriched in pathways of cancer cell biology, such as the signaling of activated point mutants of FGFR1 and recycling of bile acids and salts (Figure 2B). The gene discussed is FGFR1; the disease is cancer.